Imaging and monitoring HER2 expression in breast cancer during trastuzumab therapy with a peptide probe 99m Tc-HYNIC-H10F

Conclusions99mTc-HYNIC-H10F specifically accumulates in HER2-positive tumors. Compared with trastuzumab,99mTc-HYNIC-H10F binds to a different domain of HER2 antigen, providing new opportunities to monitor HER2 expression levels before/during/after trastuzumab treatment for more effective personalized treatment.
Source: European Journal of Nuclear Medicine and Molecular Imaging - Category: Nuclear Medicine Source Type: research